There were 2,369 press releases posted in the last 24 hours and 440,398 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Zai Lab Announces Dosing of First Patient in Phase 3 China Registration Trial of ZL-2306 (niraparib) for First-Line Maintenance Therapy in Platinum Responsive Ovarian Cancer

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image